We develop enzyme-based solutions for an optimized synthesis of Biologics, such as mRNA vaccines and therapeutics and ADCs (antibody-drug-conjugates). Our enzyme immobilization and shielding technology increases stability while maintaining the enzyme’s activity high. There is no loss of enzyme during the process as a special shielding of the immobilized enzyme prevents the biocatalyst from leaching. The main challenge in nucleic acid manufacturing including purification steps are significant high costs. Raw materials are only used once, resulting in high waste. Purification steps account for 80% of total operational costs and the costs for covid-19 vaccines were 10 USD/vaccine administration and industry goals are to reduce these costs by a factor of 5.
The cost-saving potential and efficiency gains by applying INOFEA’s enzyme technology are particularly noteworthy, especially considering the current challenges in nucleic acid manufacturing. By enabling continuous and semi-continuous processes with reduced raw material consumption, labour costs, and product variations, our technology aligns well with industry goals of reducing production costs and streamlining processes.
Moreover, the environmental benefits of our approach, such as less waste and reduced energy consumption, contribute to sustainability efforts—an increasingly important consideration in pharmaceutical manufacturing.
By simplifying registration processes and speeding up time to market, INOFEA's solutions not only offer economic advantages but also contribute to the broader goal of accelerating the availability of vital vaccines and therapeutics to patients worldwide.
Anne Timm joined INOFEA AG, a company offering tailor-made enzyme solutions for production processes of high value compounds, in 2018 as Chief Business Officer. In spring 2019 she became the Chief Executive Officer of the company.
Before joining INOFEA AG, she worked as Business Unit Head at Schoeller Medical AG located in Switzerland in the field of B2B for innovative textiles and technologies for the medical device market. Previously Anne was the global key account manager in an international chemical company for crop protection, personal care and household products and sales team leader for cosmetic and pharmaceutical raw materials. Anne had profit & loss responsibility for a global business line and was engaged in business development for international markets. Professional project management has been the base to guarantee introduction of new products and sales concepts. During her professional career she achieved a profound knowledge and experience as key account manager, business developer, leading business units, marketing, project-, product- as well as sales management by building up a direct and indirect sales team to attract and retain high profile clients. Education: University degree in biology, PhD in toxicology from the Technical University in Darmstadt, Germany.
